1. Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am 2003; 17: 59-85.
2. Ramírez-Soto M, Aguilar-Ancori E, Tirado-Sánchez A, Bonifaz A. Ecological determinants of sporotrichosis etiological agents. J Fungi 2018; 4: 95.
3. Schenck BR. On refractory subcutaneous abscesses caused by a fungus possibly related to the Sporotricha. Bull Johns Hopkins Hosp 1898; 9: 286–290.
4. Link HF. Observationes in ordines plantarum naturales. Dissertatio I. Magazin der Gesellschaft Naturforschenden Freunde Berlin 1809; 3: 3–42.
5. Rodrigues AM, Della Terra PP, Gremiao ID, Pereira SA, Orofino-Costa R, de Camargo ZP. The threat of emerging and re-emerging pathogenic Sporothrix species. Mycopathologia 2020; 185:
813–842.
6. Queiroz-Telles F, Buccheri R, Benard, G. Sporotrichosis in immunocompromised hosts. J Fungi 2019; 5: 8.
7. Gremião IDF, Miranda LHM, Reis EG, Rodrigues AM, Pereira SA. Zoonotic epidemic of sporotrichosis: Cat to human transmission. PLoS Pathog 2017; 13: e1006077.
8. Bonifaz A, Vázquez-González D. Diagnosis and treatment of lymphocutaneous sporotrichosis: What are the options? Curr Fungal Infect Rep 2013; 7: 252–259.
9. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin
Infect Dis 2007; 45: 1255–1265.
10. Aung AK, Teh BM, Mc Grath C, Thompson PJ. Pulmonary sporotrichosis: Case series and systematic analysis of literature on clinico-radiological patterns and management outcomes. Med
Mycol 2013: 51: 534–544.
11. de Hoog GS, Guarro J, Gené J, et al. Atlas of clinical fungi. 4th web-ed. Westerdijk Institute, Utrecht and Universitat Rovira i Virgili, Reus; 2019.
12. Munhoz LS, Poester VR, Severo CB, et al. Update of the Epidemiology of the Sporotrichosis Epidemic in the State of Rio Grande Do Sul, Brazil. Mycoses 2022; 65: 1112–1118.
13. Marimon R, Gené J, Cano J, Trilles L, Dos Santos Lazéra M, Guarro J. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol 2006; 44: 3251–3256.
14. Rex JH, Okhuysen PC. Sorothrix schenckii. In: Bennett JE, Dolin R, Blaser MJ,eds. Principles and Practice of Infectious Diseases. Philadelphia, Elsevier Churchill Livingstone: 2015.
15. de Hoog GS, Vitale RG. Bipolaris, Exophiala, Scedosporium, Sporothrix and other dematiaceous fungi. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical
Microbiology. Washington D.C, ASM Press; 2007.
16. Gurcan S, Konuk E, Kilic H, Otkun M, Ener B. Sporotrichosis, a disease rarely reported from Turkey, and an overview of Turkish literature. Mycoses 2007; 50: 426-429.
17. Mahajan VK. Sporotrichosis: An overview and therapeutic options. Dermatol Res Pract 2014; 2014: 272376.
18. Rodrigues AM, Gonçalves SS, de Carvalho JA, Borba-Santos LP, Rozental S, Camargo ZP. Current progress on epidemiology, diagnosis, and treatment of sporotrichosis and their future trends.
J Fungi 2022; 8: 776.
19. Romeo O, Scordino F, Criseo G. New insight into molecular phylogeny and epidemiology of Sporothrix schenckii species complex based on calmodulin-encoding gene analysis of Italian
isolates. Mycopathologia 2011; 172: 179–186.
20. Madrid H, Cano J, Gene J, Bonifaz A, Toriello C, Guarro J. Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev Iberoam De Micol 2009; 26: 218–222.
21. Koç AN, Ukşal Ü, Oymak O. Case report. Successfully treated subcutaneous infection with Sporothrix schenckii in Turkey. Mycoses 1999; 44: 330-333.
22. Karakayalı G, Lenk N, Alli N, Güngör E, Artüz F. Itraconazole therapy in lymphocutaneous sporotrichosis: A case report and review of the literature. Cutis 1998; 61: 106-108.
23. Serarslan G, Atik E. A case report of sporotrichosis from Turkey. Case Rep Clin Pract Rev 2004; 5: 297-299.
24. Coskun B, Saral Y, Akpolat N, Ataseven A, Cicek D. Sporotrichosis successfully treated with terbinafine and potassium iodide: Case report and review of the literature. Mycopathologia 2004;
158: 53-56.
25. Ozcan A, Senol M, Karaca S, Sener S, Polat M, Ozerol IH. A case of sporotrichosis treated with itraconazole. Med Mycol 2003; 41: 443-445.
26. de Carvalho JA, Beale MA, Hagen F, et al. Trends in the molecular epidemiology and population genetics of emerging Sporothrix species. Stud Mycol 2021; 10: 100129.
27. Schubach A, Schubach TMP, de Barros MBL, Wanke B. Cat-transmitted sporotrichosis, Rio de Janeiro, Brazil Emerg Infect Dis 2005; 11: 1952–1954.
28. De Barros MBL, de Schubach AO, do Valle ACF, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: Description of a series of cases. Clin Infect Dis 2004; 38: 529–535.
29. de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes, et al. Treatment of cutaneous sporotrichosis with Itraconazole—Study of 645 patients. Clin Infect Dis 2011; 52: e200-206.
30. Conceição-Silva F, Morgado FN. Immunopathogenesis of human sporotrichosis: what we already know. J Fungi 2018; 4: 89.
31. Ener B. Sporothrix shenckii. In: Topçu AW, Söyletir G, eds. Enfeksiyon Hastalıkları ve Mikrobiyolojisi. 4.baskı. Nobel Tıp Kitabevi. İstanbul; 2017.
32. Boyce KJ, Andrianopoulos A. Fungal dimorphism: The switch from hyphae to yeast is a specialized morphogenetic adaptation allowing colonization of a host. FEMS Microbiol Rev 2015; 39:
797–811.
33. Teixeira PAC, De Castro RA, Ferreira FRL, et al. L-DOPA accessibility in culture medium increases melanin expression and virulence of Sporothrix schenckii yeast cells. Med Mycol 2010; 48: 687–695.
34. Hernández-Chávez MJ, Pérez-García LA, Niño-Vega GA, Mora-Montes HM. Fungal Strategies to Evade the Host Immune Recognition. J Fungi 2017; 3: 51.
35. Castro RA, Kubitschek-Barreira PH, Teixeira PAC, et al. Differences in Cell Morphometry, Cell Wall Topography and Gp70 Expression Correlate with the Virulence of Sporothrix brasiliensis
Clinical Isolates. PLoS ONE 2013; 8: e75656.
36. Da Daniel Rosa W, Gezuele E, Calegari L, Goñi F. Asteroid body in sporotrichosis. Yeast viability and biological significance within the host immune response. Med Mycol 2008; 46: 443–448.
37. Arrillaga-Moncrieff I, Capilla J, Mayayo E, et al. Different virulence levels of the species of Sporothrix in a murine model. Clin Microbiol Infect 2009; 15: 651–655.
38. Camacho E, León-Navarro I, Rodríguez-Brito S, Mendoza M, Niño-Vega GA. Molecular epidemiology of human sporotrichosis in Venezuela reveals high frequency of Sporothrix globosa.
BMC Infect Dis 2015; 15: 94.
39. Arenas R, Sánchez-Cardenas CD, Ramirez-Hobak L, RuizArriga LF, VegaMemije ME. Sporotrichosis: from KOH to molecularbiology. J Fungi 2018; 4: 62.
40. Saba R. Sporotrikoz. İç Hastalıkları Dergisi 2008; 15: 94-98.
41. Rodrigues AM, Orofino-Costa R, de Camargo ZP. Sporothrix spp. In Pocket Guide to Mycological Diagnosis, 1st ed.; Cordeiro Rde, A., Ed.; CRC Press: Boca Raton, FL, USA, 2019.
42. Gezuele E, Da Rosa D. Importance of the sporotrichosis asteroid body for the rapid diagnosis of sporotrichosis. Rev Iberoam De Micol 2005; 22: 147–150.
43. Reiss E, Shadomy HJ, Lyon GM, eds. Fundamental Medical Mycology. New Jersey, Wiley-Blackwell; 2012.
44. Morris-Jones R. Sporotrichosis. Clin Exp Dermatol 2002; 27: 427–431.
45. Alvarado P, Ostos A, Franquiz N, Roschman-González A, Zambrano EA, Mendoza M. Serological diagnosis of sporotrichosis using an antigen of Sporothrix schenckii sensu stricto mycelium.
Investig Clin 2015; 56: 111–122.
46. Bonifaz A, Vázquez-González D. Sporotrichosis: An update. G Ital Derm Venereol 2010; (145): 659–673.
47. Kano R, Matsuoka A, Kashima M, et al. Detection of Sporothrix schenckii chitin synthase 1 (CHS1) gene in biopsy specimens from human patients with sporotrichosis. J Derm Sci 2003; 33: 73–74.
48. Kano R, Nakamura Y, Watanabe S, Tsujimoto H, Hasegawa A. Identification of Sporothrix schenckii based on sequences of the chitin synthase 1 gene. Mycoses 2001; 44: 261–265.
49. Espinel-Ingroff A, Abreu DPB, Almeida-Paes R, et al. Multicenter and international study of MIC/MEC distributions for definition of epidemiological cutoff values (ECVs) for species of
Sporothrix identified by molecular methods. Antimicrob Agents Chemother 2017; 61: e01057-17.
50. Sharma B, Sharma AK, Sharma U. Sporotrichosis: A comprehensive review on recent drug-based therapeutics and management. Curr Derm Rep 2022; 11: 110–119.
51. Gremião IDF, Miranda LHM, Pereira-Oliveira GR, et al. Advances and challenges in the management of feline sporotrichosis. Rev Iberoam Micol 2022; 39: 3-4.
52. De Lima Barros MB, Schubach TM, Galhardo MC, et al. Sporotrichosis: An emergent zoonosis in Rio de Janeiro. Mem Inst Oswaldo Cruz 2001; 96: 777–779.
53. Francesconi G, do Valle ACF, Passos SL, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia 2011;
171: 349–354.
54. Carolus H, Pierson S, Lagrou K, Van Dijck P. Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance. J Fungi 2020; 6: 321.
55. Rodrigues AM, de Hoog GS, de Camargo ZP. Feline sporotrichosis. In: Seyedmousavi S, de Hoog GS, Guillot J, Verweij PE, eds. Emerging and epizootic fungal infections in animals. Cham,
Springer: 2018.
56. de Araujo ML, Rodrigues AM, Fernandes GF, de Camargo ZP, de Hoog GS. Human sporotrichosis beyond the epidemic front reveals classical transmission types in Espı´rito Santo, Brazil.
Mycoses 2015; 58: 485–490.
57. Kalkancı A. Subkütanöz Mikozlar. In: Murray PR, Rosenthal KS, Pfaller MA, eds. (Çeviri eds. AD Us, A Başustaoğlu). Tıbbi Mikrobiyoloji. 7. Baskı. Ankara, Pelikan Kitapevi; 2016.
58. Polat SH. Subkutan Mikozlar. Topçu AW, Söyletir G, Doğanay M, eds. Enfeksiyon Hastalıkları ve Mikrobiyolojisi. 3. Baskı. İstanbul, Nobel Tıp Kitabevi; 2008.
59. Bhagwat PV, Tophakhane RS, Kudligi C, Noronha T. Multiple asymptomatic verrucous plaques over the legs. Indian J Dermatol Venereol Leprol 2010; 76: 86.
60. Medlar EM. A cutaneous infection caused by a new fungus Phialophora verrucosa with a study of the fungus. J Med Res 1915; 32: 507-522.
61. Agarwal R, Singh G, Ghosh A, Verma KK, Pandey M, Xess I. Chromoblastomycosis in India: Review of 169 cases. PLoS Negl Trop Dis 2017; 11: e0005534.
62. Devi BK, Celine MI, George S, Shanimole PE, Vargese S. Chromoblastomycosis: A clinico-investigative study of 42 cases. Indian J Dermatopathol Diagn Dematol 2022; 9: 44-46.
63. Queiroz-Telles F, de Hoog GS, Santos DWCL, et al. Chromoblastomycosis. Clin Microbiol Rev 2017; 30: 233-276.
64. de Azevedo CMPS, Gomes RR, Vicente VA, et al. Fonsecaea pugnacius, a novel agent of disseminated chromoblastomycosis. J Clin Microbiol 2015; 53: 2674 –2685.
65. de Hoog GS, Nishikaku AS, Fernandez-Zeppenfeldt G, et al. Molecular analysis and pathogenicity of the Cladophialophora carrionii complex, with the description of a novel species 2007; Stud
Mycol 58: 219 –234.
66. Larone DH, eds. Medically Important Fungi: A Guide to Identification. 5th Edition. ASM Press, 2013.
67. Zeng JS, Sutton DA, Fothergill AW, Rinaldi MG, Harrak MJ, de Hoog GS. Spectrum of clinically relevant Exophiala species in the United States. J Clin Microbiol 2007; 45: 3713–3720.
68. Lu S, Lu C, Zhang J, Hu Y, Li X, Xi L. Chromoblastomycosis in mainland China: a systematic review on clinical characteristics. Mycopathologia 2013; 175: 489-495.
69. Queiroz-Telles F, Nucci M, Colombo AL, Tobón A, Restrepo A. Mycoses of implantation in Latin America: An overview of epidemiology, clinical manifestations, diagnosis and treatment.
Med Mycol 2011; 49: 225–236.
70. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2009; 47: 3–15.
71. Esterre P, Andriantsimahavandy A, Raharisolo C. Natural history of chromoblastomycosis in Madagascar and the Indian Ocean. Bull Soc Pathol Exot 1997; 90: 312–317.
72. Yusuf S, Çalışır B, Öztürk F, ve ark. Esmer mantarları ne kadar iyi tanıyoruz? İki Olgu. 7. Ulusal Klinik Mikrobiyoloji Kongresi Bildiri Kitabı, Bodrum; 2023.
73. La Hoz RM, Baddley JW. Subcutaneous fungal infections. Curr Infect Dis Rep 2012; 14: 530-539.
74. Queiroz-Telles F, Santos DWCL, Pedroso C. Fungal infections of implantation (chromoblastomycosis, mycetoma, entomophthoramycosis, and lacaziosis). In: Hospenthal D, Rinaldi MG, eds.
Diagnosis and treatment of fungal infections. 2nd edition. Basel, Switzerland, Springer International Publishing; 2015.
75. Queiroz-Telles F, Santos DWCL. Challenges in the therapy of chromoblastomycosis. Mycopathologia 2013; 175: 477– 488.
76. Badali H, Fernandez-Gonzales M, Mousavi B, et al. Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba. Mycopathologia 2013; 175: 439 – 444.
77. Vidal MS, Castro LG, Cavalcante SC, Lacaz CS. Highly specific and sensitive, immunoblot-detected 54 kDa antigen from Fonsecaea pedrosoi. Med Mycol 2004; 42: 511–515.
78. Garnica M, Nucci M, Queiroz-Telles F. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr
Opin Infect Dis 2009; 22: 559 –563.
79. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo
2005; 47: 339 –346.
80. Azevedo CDM, Marques SG, Resende MA, et al. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses 2008; 51:341–344.
81. de Sousa TMG, Belda WJ, Spina R, et al. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis 2014; 58: 1734 –1737.
82. Relhan V, Mahajan K, Agarwal P, Garg VK. Mycetoma: An Update. Indian J Dermatol 2017; 62: 332- 340.
83. van de Sande WW. Global burden of human mycetoma: A systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7: e2550.
84. Nenoff P, van de Sande WW, Fahal AH, Reinel D, Schöfer H. Eumycetoma and actinomycetoma – an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy.
J Eur Acad Dermatol Venereol 2015; 29: 1873-1883.
85. Pinoy E. Actinomycoses and mycetomas. Bull Inst Past 1913; 11: 929–938.
86. Sow D, Ndiaye M, Sarr L, et al. Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018. PLoS One 2020; 15(4): e0231871.
87. Fahal AH, Suliman SH, Hay R. Mycetoma: The Spectrum of Clinical Presentation. Trop Med Infect Dis 2018; 3: 97.
88. Emery D, Denning DW. The global distribution of actinomycetoma and eumycetoma. PLoS Negl Trop Dis 2020; 14: e0008397.
89. de Hoog GS, Adelmann D, Ahmed AO, van Belkum A. Phylogeny and typification of Madurrella mycetomatis, with a comparison of other agents of eumycetoma. Mycoses 2004; 47: 121-130.
90. Bounfrate D, Gobbi F, Angheben A, et al. Autochthonous cases of mycetoma in Europe: report of two cases an review of literature. PloS One. 2014; 9: e100590.
91. Ahmed SA, van de Sande WWJ, Stevens DA, et al. Revision of agents of black-grain eumycetoma in the order Pleosporales. Persoonia 2014; 33: 141-154.
92. Gilgado F, Gené J, Cano J, Guarro J. Heterothalism in Scedosporium apiospermum and description of its teleomorph Pseudollescheria apiosperma sp. nov. Med Mycol 2010; 48: 122-128.
93. van de Sande W, Fahal A, Ahmed SA, Serrano JA, Bonifaz A, Zijlstra E. Closing the mycetoma knowledge gap. Med Mycol 2018; 56: 153–164.
94. van de Sande WW. Global burden of human mycetoma: A systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7: e2550.
95. Aslan NÇ, Fındık O, Özer T, Soydan S, Eruyar AT. Radyolojik Bulgularla Tanı Konulan Bilateral Miçetoma: Olgu Sunumu. Kocaeli Medical J 2016; 5: 45-48.
96. Barış A, Öncül A, Öztürk K, Barış A, Aykut S, Aktaş E. Mikolojik Tanının Önemi: 20 Yıl İhmal Edilen Bir Scedosporium apiospermum Kompleks Miçetoma Olgusu. Mikrobiyol Bul 2021; 55:
256-264.
97. Uzun H, Yardımcı S. Ön Etmoid Sinüs Lokalizasyonlu Miçetoma Olgusu. K.B.B. ve Baş Boyun Cerrahisi Dergisi, 2000, 8 (1): 58-61.
98. Das L, Dahiya D, Gupta K, at al. Eumycetoma of the Foot due to Fusarium solani in a Person with Diabetes Mellitus: Report of a Case and Review of Literature. Mycopathologia 2021; 186:
277–288.
99. Lichon V, Khachemoune A. Mycetoma: A review. Am J Clin Dermatol.2006; 7: 315–321.
100. Adam SAY, Ahmed ES, Adam SIM, Abdallah OB, Siddig EE, Fahal AH. Eumycetoma with pulmonary dissemination an unusualcomplication: Case series and literature review. PLoS Negl Trop
Dis 2022; 16:e0010867.
101. Arenas R, Vega-Mémije ME, Rangel-Gamboa L. Eumycetoma: present status and perspective. Gac Med Mex 2017; 153: 763-772.
102. Hao X, Cognetti M, Burch-Smith R, Mejia EO, Mirkin G. Mycetoma: Development of Diagnosis and Treatment. J Fungi 2022; 8: 743.
103. Madden C, Spector A, Siddiqui S, Mirkin G, Yim J, Hao X. Dermatofibrosarcoma Protuberans on Adult Toes: A Case Report and Review of the Literature. Anticancer Res 2019; 39: 2105–2111.
104. Hao X, Yim J, Chang S, et al. Acral Lentiginous Melanoma of Foot and Ankle: A Clinicopathological Study of 7 Cases. Anticancer Res 2019; 39: 6175–6181.
105. Tritto M, Procop GW, Billings ST, Mirkin G, Hao X. Eumycetoma, A Neglected Tropical Disease in the United States. J Am Podiatr Med Assoc 2021; 111:6.
106. Ponka D, Baddar F. Microscopic potassium hydroxide preparation. Can Fam Physician Med Fam Can 2014; 60: 57.
107. Ahmed AA, van de Sande W, Fahal AH. Mycetoma laboratory diagnosis: Review article. PLoS Negl Trop Dis 2017; 11: e0005638.
108. Salinas-Carmona MC, Welsh O, Casillas SM. Enzyme-linked immunosorbent assay for serological diagnosis of Nocardia brasiliensis and clinical correlation with mycetoma infections. J Clin
Microbiol 1993; 31: 2901–2906.
109. Agarwal P, Jagati A, Rathod SP, Kalra K, Patel S, Chaudhari M. Clinical Features of Mycetoma and the Appropriate Treatment Options. Res Rep Trop Med 2021; 12: 173–179.
110. Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006; 75: 1106–1107.
111. Karrakchou B, Boubnane I, Senouci K, Hassam B. Madurella mycetomatis infection of the foot: A case report of a neglected tropical disease in a non-endemic region. BMC Dermatol 2020; 20: 1.
112. Cárdenas-de la Garza JA, Welsh O, Cuéllar-Barboza A, et al. Clinical characteristics and treatment of actinomycetoma in northeast Mexico: A case series. PLoS Negl Trop Dis 2020; 14:
e0008123.
113. Suleiman SH, Wadaella S, Fahal AH. The Surgical Treatment of Mycetoma. PLoS Negl Trop Dis 2016; 10: e0004690.
114. Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, et al. Lobomycosis: an emerging disease in humans and delphinidae. Mycoses 2012; 55: 298–309.
115. Lobo JO. New species of blastomycosis [in Portuguese]. Bras Med 1930; 44: 1227.
116. Vilela R, De Hoog S, Bensch K, Bagagli E, Mendoza L. A taxonomic review of the genus Paracoccidioides, with focus on the uncultivable species. PLoS Negl Trop Dis 2023; 17: e0011220.
117. Symeres S. A possible case of Lobo’s diseases acquired in Europe from a bottle-nosed dolphin (Tursiops truncates). Bull Société Pathol Exot Fil 1983; 76: 777–784.
118. Lacaz CS, Baruzzi RG, Rosa MCB. Doença de Jorge Lobo. EDUSP; 1986; 1–92.
119. de Brito AC, Quaresma JAS. Lacaziose (doença de Jorge Lobo): Revisão e atualização. An Bras Dermatol 2007; 82: 461–474.
120. Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: Fungal tropical diseases. J Am Acad Dermatol 2005; 53: 931–951.
121. Saint-Blancard P, Maccari F, Le Guyadec T, Lanternier G, Le Vagueresse R. Lobomycosis: A mycosis seldom observed in metropolitan France. Ann Pathol 2000; 20: 241–244.
122. Burns RA, Roy JS, Woods C, Padhye AA, Warnock DW. Report of the first human case of Lobomycosis in United States. J Clin Microb 2000; 38: 1283–1285.
123. Al-Daraji WI, Husain E, Robson A. Lobomycosis in African patients. Br J Dermatol 2008; 159: 231–266.
124. Suárez JA, Cerrud B, Pachar M, et al. Human Lobomycosis Caused by Paracoccidioides (Lacazia) loboi, Panama, 2022. Emerg Infect Dis 2023; 29: 2513–2517.
125. Nogueira L, Mendes L, Rodrigues CA, Santos M, Talhari S, Talhari C. Lobomycosis and squamous cell carcinoma. An Bras Dermatol 2013; 88: 293–295.
126. Miranda MFR, Silva AJG. Vinyl adhesive tape effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidiodomycosis. Diagn Microbiol Infect Dis 2005; 52: 39-43.
127. Beltrame A, Danesi P, Farina C, at al. Molecular confirmation of lobomycosis in an Italian traveler acquires in the Amazon Region of Venezuela. Am J Trop Med Hyg 2017; 97: 1757–1760.
128. Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F. Lobomycosis: Epidemiology, clinical presentation, and management options. Ther Clin Risk Manag 2014; 10: 851-860.
129. Carneiro FP, Maia LB, Moraes MA, et al. Lobomycosis: diagnosis and management of relapsed and multifocal lesions. Diagn Microbiol Infect Dis 2009; 65: 62–64.
130. Pasqualotto AC, Jaskulski Filho SD, Sena MG, Santos A, Severo M. Posaconazole for lobomycosis. Braz J Infect Dis 2021; 25: 101576.
131. Gonçalves FG, Rosa PS, Belone AFF, et al. Multidrug therapy for leprosy can cure patientes with lobomycosis in Acre State, Brazil: A proof of therapy study. Am J Trop Med Hyg 2020; 1